Search for Clinical Trial Results
Philadelphia Chromosome - 26 Studies Found
Status | Study |
No longer available |
Study Name: Compassionate Use Ponatinib Condition:
|
Completed |
Study Name: Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects Condition: Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML) Date: 2011-06-07 Interventions:
|
Active, not recruiting |
Study Name: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Condition:
|
Active, not recruiting |
Study Name: Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Condition:
|
Completed |
Study Name: Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia Condition: Leukemia Date: 2005-10-25 Interventions:
|
Completed |
Study Name: Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias Condition: Chronic Myelogenous Leukemia Date: 2008-12-17 Interventions: Drug: SKI-606 (Bosutinib) Formulation: 100 mg Capsule for |
Completed |
Study Name: Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Condition: Philadelphia Chromosome-positive Chronic Myelocytic Leukemia Date: 2009-08-26 Interventions: Procedure: Stem cell transplantation Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4 |
Completed |
Study Name: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias Condition: Chronic Myeloid Leukemia Date: 2005-12-02 Interventions: Drug: Bosutinib Part 1, starting dose 400 mg oral, daily d |
Recruiting |
Study Name: A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL Condition:
|
Completed |
Study Name: Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy Condition: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Date: 2011-10-14 Interventions: Drug: Nilotinib + LDE225 Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosi |